ArticleRenal failure2026
Effect of IV ferric carboxymaltose treatment on platelet counts and serum transferrin levels in CKD patients not on dialysis with iron deficiency: potential implications for thrombogenicity.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia and iron deficiency (ID) are common complications in chronic kidney disease (CKD). Beyond their haematological impact, ID has been linked to heightened thrombotic risk, partly through increases in platelet counts and circulating transferrin. We investigated whether correction of ID with intravenous ferric carboxymaltose (FCM) could modify these parameters in CKD patients with mild anemia. This prospective single-centre study included 41 patients with non-dialysis CKD (mean age 74.9 ± 9.5 years, 66% male), mild anemia, and ID. All received IV FCM (mean dose 616.2 ± 163.8 mg) and were analyzed at baseline and after 4 weeks. Hemoglobin (Hb) levels increased non-significantly (10.9 ± 0.4 vs. 11.1 ± 0.4 g/dL, p = NS). In contrast, platelet counts (240 ± 86 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.